会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 112. 发明公开
    • PERSONALIZED TUMOR BIOMARKERS
    • 个性化肿瘤生物标志物
    • EP2536854A4
    • 2013-08-07
    • EP11745196
    • 2011-02-17
    • UNIV JOHNS HOPKINS
    • VOGELSTEIN BERTKINZLER KENNETH WVELCULESCU VICTORDIAZ LUISLEARY REBECCA J
    • C12Q1/68C12N15/11C40B40/06
    • C12Q1/6886C12Q2600/156
    • Clinical management of human cancer is dependent on the accurate monitoring of residual and recurrent tumors. We have developed a method, called personalized analysis of rearranged ends (PARE), which can identify translocations in solid tumors. Analysis of four colorectal and two breast cancers revealed an average of nine rearranged sequences (range 4 to 15) per tumor. Polymerase chain reaction with primers spanning the breakpoints were able to detect mutant DNA molecules present at levels lower than 0.001% and readily identified mutated circulating DNA in patient plasma samples. This approach provides an exquisitely sensitive and broadly applicable approach for the development of personalized biomarkers to enhance the clinical management of cancer patients.
    • 人类癌症的临床管理取决于对残留和复发性肿瘤的准确监测。 我们开发了一种称为重排末端(PARE)的个性化分析方法,可以识别实体瘤易位。 对4例结直肠癌和2例乳腺癌的分析显示,每个肿瘤平均有9个重排序列(范围4至15)。 聚合酶链反应与穿过断点的引物能够检测出存在于低于0.001%水平的突变DNA分子,并且容易鉴定出患者血浆样品中突变的循环DNA。 这种方法为个体化生物标志物的开发提供了一种非常灵敏和广泛适用的方法,以加强癌症患者的临床管理。